Eli Lilly’s Tirzepatide Shows Sustained Weight Loss in 176-Week Study
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has released 176-week follow-up data from...
Clinical trial results
Gan & Lee’s GZR18 Shows Significant Weight Loss in Phase IIb Study at ObesityWeek 2024
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the oral presentation...
BeyondSpring Presents Positive Phase II Data for Plinabulin Combination Therapy in NSCLC at SITC
BeyondSpring Inc. (NASDAQ: BYSI), a US-based biotech company, has announced the presentation of the latest...
Abbisko Therapeutics’ Pimicotinib Meets Primary Endpoint in Phase III MANEUVER Study for TGCT
hanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has revealed positive top-line results from the...
AstraZeneca’s Tezspire Meets Phase III Co-Primary Endpoints in CRSwNP Study
AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced positive high-level results...
Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024
Alphamab Oncology (HKG: 9966), a China-based biopharmaceutical company, has announced the presentation of the latest...
Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial
Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a...
HutchMed to Present Updated Data from Solvleplenib ESLIM-01 Phase III Trial at ASH and ESMO Congress 2024
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced plans to present new and...
CARSgen Therapeutics Presents Latest CAR-T Data at ASH Annual Meeting
CARSgen Therapeutics Holdings Ltd (HKG: 2171), a China-based specialist in chimeric antigen receptor (CAR)-T cell...
Ascentage Pharma to Present Olverembatinib and Lisaftoclax Clinical Data at ASH Annual Meeting
China-based Ascentage Pharma (HKG: 6855) has announced that it will present the results of multiple...
CStone Pharmaceuticals Presents CS5001 Clinical Data at the ASH Annual Meeting
China-based CStone Pharmaceuticals (HKG: 2616) has announced the presentation of the latest clinical data on...
Roche to Showcase 40+ Abstracts on Blood Disorders at ASH Annual Meeting
Swiss pharmaceutical giant Roche (SWX: ROG) has announced plans to present over 40 abstracts across...
Legend Biotech to Showcase CARTITUDE-4 Trial Data on Carvykti at ASH Annual Meeting
China-based Legend Biotech Corporation (NASDAQ: LEGN) is set to present new data on minimal residual...
China Grand Pharmaceutical Completes Phase III Clinical Study for Post-Cataract Surgery Treatment
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the successful completion...
J&J MedTech Completes Pilot Enrollment for OMNY-AF Study on Atrial Fibrillation Treatment
US major Johnson & Johnson (J&J, NYSE: JNJ) MedTech has announced the completion of pilot...
Teva Pharmaceutical Reports Positive Phase III Results for TEV-‘749 in Schizophrenia Trial
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has released new positive data on social functioning...
Novo Nordisk’s Semaglutide Meets Primary Endpoints in ESSENCE Phase III Study for MASH
Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO; CPH: Novo-B) has announced that part 1 of...
Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...
Sino Medical Reports Five-Year PIONEER Study Results for HT Supreme Stent System
Sino Medical Sciences Technology Inc. (SHA: 688108), based in China, has announced the five-year follow-up...
Zai Lab Reports Positive Phase III Results for KarXT, Showcasing Efficacy in Psychiatric Conditions
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced encouraging topline results from...